Pharmacologic treatment of first-episode schizophrenia: A review of the literature

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 1, 2012, Pages

  Thomas, Shibu P ^a   Nandhra, Harpal Sing ^a   Singh, Swaran P ^b  

^a University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; ANOREXIA; ANXIETY; ANXIETY DISORDER; BLOOD DISEASE; BLURRED VISION; BRADYCARDIA; COGNITIVE THERAPY; COMORBIDITY; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MISUSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; EDEMA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; ILEUS; INCREASED APPETITE; INSOMNIA; INSULIN RESISTANCE; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; METABOLIC DISORDER; MYOCARDITIS; MYOPATHY; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PSYCHOEDUCATION; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TACHYCARDIA; TREATMENT INDICATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84864018543     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11r01198     Document Type: Review

References (64)

1. Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46(1):56-72. PubMed doi:10.1016/S0006-3223(99)00067-0 Show Abstract
2. Hirvonen J, van Erp TG, Huttunen J, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005;62(4):371-378. PubMed doi:10.1001/archpsyc.62.4.371 Show Abstract
3. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22(9):3708-3719. PubMed Show Abstract
4. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267-271. PubMed doi:10.1038/nn804 Show Abstract
5. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192(4238):481-483. PubMed doi:10.1126/science.3854 Show Abstract
6. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. PubMed doi:10.1176/appi.ajp.160.1.13 Show Abstract
7. Murray GK. The emerging biology of delusions. Psychol Med. 2011;41(1):7-13. PubMed doi:10.1017/S0033291710000413 Show Abstract
8. Woolley DW, Shaw E. A biolochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA. 1954;40(4):228-231. PubMed
9. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999a;156(2):286-293. PubMed Show Abstract
10. Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol. 1999;19(3):222-232. PubMed doi:10.1097/00004714-199906000-00004 Show Abstract
11. Pomarol-Clotet E, Honey GD, Murray GK, et al. Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry. 2006;189(2):173-179. PubMed doi:10.1192/bjp.bp.105.015263 Show Abstract
12. Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry. 2008;165(8):931-936. PubMed doi:10.1176/appi.ajp.2008.08050769Show Abstract
13. Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 2010;11(2, Pt 2):208-219. PubMed doi:10.3109/15622970801908047 Show Abstract
14. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PubMed Show Abstract
15. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004;4(1):53-57. PubMed doi:10.1016/j.coph.2003.09.010 Show Abstract
16. Gelder M, Harrison P, Cowen P. Drugs and other physical treatments. In: Gelder M, Harrison P, Cowen P, eds. Shorter Oxford Textbook of Psychiatry, 5th Edition. New York, NY: Oxford University Press; 2006.
17. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369 [Review]. PubMed doi:10.1176/appi.ajp.158.3.360Show Abstract
18. Khunti K, Davies M. Metabolic syndrome. BMJ. 2005;331(7526):1153-1154. PubMed doi:10.1136/bmj.331.7526.1153 Show Abstract
19. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19-28. PubMed doi:10.1001/archpsyc.62.1.19 Show Abstract
20. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-981. PubMed doi:10.1176/appi.ajp.157.6.975 Show Abstract
21. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561-566. PubMed doi:10.1176/appi.ajp.159.4.561 Show Abstract
22. Smith M, Hopkins D, Peveler RC, et al. First-v second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411. PubMeddoi:10.1192/bjp.bp.107.037184 Show Abstract
23. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):492-501. PubMedShow Abstract
24. De Hert M, Van Eyck D, Hanssens L, et al. Oral glucose tolerance tests in treated patients with schizophrenia: data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry. 2006;21(4):224-226. PubMed doi:10.1016/j.eurpsy.2005.05.011Show Abstract
25. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349. PubMeddoi:10.1176/appi.ajp.161.8.1334 Show Abstract
26. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001;62(suppl 27):27-34. PubMed
27. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 10th Edition. London, England: Informa Healthcare; 2009.
28. National Institute for Clinical Excellence. Clinical Guideline 1. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, England: NICE; 2009.
29. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376. PubMed doi:10.1136/bmj.321.7273.1371 Show Abstract
30. Jones PB, Barnes T, Davies L, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087. PubMed doi:10.1001/archpsyc.63.10.1079Show Abstract
31. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa051688 Show Abstract
32. Kapur S, Remington G, Jones C, et al. Does dopamine receptor occupancy predict antipsychotic response and side effects? a randomised double-blind test of hypothesis. Schizophr Res. 1999;36:242.
33. Remington G. Rational pharmacotherapy in early psychosis. Br J Psychiatry. 2005;187(suppl 48):s77-s84. doi:10.1192/bjp.187.48.s77
34. Crow TJ, MacMillan JF, Johnson AL, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148(2):120-127. PubMeddoi:10.1192/bjp.148.2.120 Show Abstract
35. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. PubMed doi:10.1001/archpsyc.56.3.241Show Abstract
36. Kissling W. The current unsatisfactory state of relapse prevention in schizophrenic psychoses: suggestions for improvement. Clin Neuropharmacol. 1991;14(suppl 2):S33-S44. PubMed Show Abstract
37. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483-488. PubMed
38. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin. 1997;14(1):1-20.
39. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992;18(3):515-542. PubMed
40. Kerwin RW, Bolonna A. Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat. 2005;11(2):101-106. doi:10.1192/apt.11.2.101
41. Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry. 2005;38(1):39-40. PubMed doi:10.1055/s-2005-837772Show Abstract
42. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001;15(4):297-301. PubMeddoi:10.1177/026988110101500409 Show Abstract
43. Barnes TRE, McEvedy CJB, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry suppl. 1996;169(31):31-40. PubMed Show Abstract
44. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia, 1: meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med. 2002a;32(5):763-782. PubMeddoi:10.1017/S0033291702005895 Show Abstract
45. Garety PA, Fowler DG, Freeman D, et al. Cognitive behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry. 2008;192(6):412-423. PubMeddoi:10.1192/bjp.bp.107.043570 Show Abstract
46. Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004;61(9):866-876. PubMed doi:10.1001/archpsyc.61.9.866Show Abstract
47. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia, 2: meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med. 2002;32(5):783-791. PubMeddoi:10.1017/S0033291702005640 Show Abstract
48. Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172(5):413-419. PubMeddoi:10.1192/bjp.172.5.413 Show Abstract
49. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007;115(4):304-309. PubMed doi:10.1111/j.1600-0447.2006.00900.x Show Abstract
50. Wade D, Harrigan S, McGorry PD, et al. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry. 2007;68(5):767-774. PubMeddoi:10.4088/JCP.v68n0517 Show Abstract
51. Green AI, Tohen MF, Hamer RM, et al; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2-3):125-135. PubMeddoi:10.1016/j.schres.2003.08.001 Show Abstract
52. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441-449. PubMed Show Abstract
53. Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br J Psychiatry.1999;174:15-22. PubMed
54. Siris S, Pollack S, Bermanzohn P, et al. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia. Schizophr Res. 2000;44(3):187-192. PubMed doi:10.1016/S0920-9964(99)00197-8 Show Abstract
55. Basu A, Pereira J, Aitchison KJ. The pharmacological management of schizophrenia. In: Stein G, Wilkinson G, editors. College Seminar Series in General Adult Psychiatry. Liverpool, England: Royal College of Physicians Publications; 2007.
56. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41(11):1203-1211. PubMed Show Abstract
57. National Institute for Clinical Excellence. Clinical Guideline 1. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, England: NICE; 2002.
58. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564. PubMeddoi:10.1001/archpsyc.60.6.553 Show Abstract
59. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. PubMed doi:10.1016/S0140-6736(08)60486-9Show Abstract
60. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222. PubMed doi:10.1176/appi.ajp.160.7.1209 Show Abstract
61. Owens DC. How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Adv Psychiatr Treat. 2008;14(1):17-28. doi:10.1192/apt.bp.107.003970
62. Harrison PJ. Metabotropic glutamate receptor agonists for schizophrenia. Br J Psychiatry. 2008;192(2):86-87. PubMed doi:10.1192/bjp.bp.107.045088Show Abstract
63. Basu A, Tsapakis E, Aitchison KJ. Pharmacogenetics and psychiatry. Curr Psychiatry Rep. 2004;6(2):134-142. PubMed doi:10.1007/s11920-004-0053-5Show Abstract
64. Stefan M, Travis M, Murry RM. Atlas of Schizophrenia. London, England: The Parthenon Publishing Group; 2002.